IL17A and psoriatic arthritis: Secukinumab is suitable for the treatment of psoriasis and psoriatic arthritis in adults who have had an inadequate response to conventional synthetic DMARDs, and for treating axial spondyloarthritis, including AS and nonradiographic axial spondyloarthritis by targeting IL17A [216].